Regulatory Effect of Huaihuasan Combined with Taohuatang on Immune Inflammation During Active Period of Ulcerative Colitis with Cold-heat Syndrome

Na LEI; Peng-fei KONG; Si-min CHEN; Xue-gui TANG

doi:10.13422/j.cnki.syfjx.20192232

您当前的位置：

首页 >

文章列表页 >

Regulatory Effect of Huaihuasan Combined with Taohuatang on Immune Inflammation During Active Period of Ulcerative Colitis with Cold-heat Syndrome

Clinic | 更新时间：2021-02-09

- Regulatory Effect of Huaihuasan Combined with Taohuatang on Immune Inflammation During Active Period of Ulcerative Colitis with Cold-heat Syndrome
- Chinese Journal of Experimental Traditional Medical Formulae Vol. 26, Issue 7, Pages: 86-91(2020)
- 作者机构：
  
  1.成都中医药大学　附属医院，成都　 610072
  2.川北医学院　附属医院，四川南充　 637002
- 作者简介：
- 基金信息：
- DOI：10.13422/j.cnki.syfjx.20192232
  CLC： R25;R256;R256.3;R289
- Received：24 July 2019，
  
  Published Online：16 August 2019，
  
  Published：05 April 2020
- 稿件说明：
移动端阅览
Na LEI, Peng-fei KONG, Si-min CHEN, et al. Regulatory Effect of Huaihuasan Combined with Taohuatang on Immune Inflammation During Active Period of Ulcerative Colitis with Cold-heat Syndrome[J]. Chinese journal of experimental traditional medical formulae, 2020, 26(7): 86-91.
DOI：

Na LEI, Peng-fei KONG, Si-min CHEN, et al. Regulatory Effect of Huaihuasan Combined with Taohuatang on Immune Inflammation During Active Period of Ulcerative Colitis with Cold-heat Syndrome[J]. Chinese journal of experimental traditional medical formulae, 2020, 26(7): 86-91. DOI： 10.13422/j.cnki.syfjx.20192232.

摘要

目的：

观察槐花散合桃花汤加减治疗溃疡性结肠炎(UC)活动期寒热错杂证的疗效及对免疫功能和炎症反应的调节作用。

方法：

将112例符合要求的患者按照随机数字表法分为观察组和对照组各56例。对照组轻度、中度患者，口服美沙拉嗪肠溶片，1.0 g/次，3次/d；重度或轻、中度患者服药4周后仍然疗效不佳者，采用醋酸泼尼松片，0.75 mg·kg

-1

·d

-1

，分3次口服。观察组西医治疗同对照组，并采用槐花散合桃花汤加减内服，1剂/d。两组疗程均为连续治疗4周。缓解期采用美沙拉嗪肠溶片，0.5 g/次，3次/d，长期维持治疗。采用改良mayo评分评价疾病活动情况，并记录临床缓解和临床有效情况，进行寒热错杂证评分，进行肠镜下黏膜表现评分和黏膜组织学的Geboes指数评分，检测外周血肿瘤坏死因子-

(TNF-

)，白细胞介素-8(IL-8)，IL-10；检测T淋巴细胞亚群水平(CD4

＋

，CD8

＋

)，以上指标治疗前后各评价1次，并记录治疗期间的不良反应，治疗后随访6个月，记录复发情况。

结果：

采用秩和检验分析中医证候疗效，观察组优于对照组(

＝1.915，

0.05)；观察组临床有效率为98.04%(50/51)，临床缓解率为94.12%(48/51)，黏膜愈合率为96.08%(49/51)，均分别高于对照组的84.00%(42/50)，78.00%(39/50)和82.00%(41/50)(

0.05)；观察组患者mayo，寒热错杂证、结肠黏膜和Geboes指数评分均低于对照组(

0.01)；观察组患者TNF-

，IL-8均低于对照组(

0.01)，IL-10水平高于对照组(

0.01)；观察组患者CD4

＋

，CD4

＋

/CD8

＋

均高于对照组，CD8

＋

较对照组低(

0.01)；观察组6个月内的复发率为10.42%(5/48)，低于对照组的30.77%(12/39)(

＝5.669，

0.05)；两组不良反应比较无统计学差异。

结论：

槐花散合桃花汤加减用于UC活动期寒热错杂证患者，可诱导UC进入缓解，抑制疾病的活度，减轻临床症状，并能调节免疫功能和炎症因子表达，减轻炎症反应，促进肠黏膜愈合，并能维持临床缓解和减少复发，临床疗效优于5-氨基水杨酸(5-ASA)/糖皮质激素的西医治疗方案。

Abstract

Objective:

To observe effect of addition and subtraction therapy of Huaihuasan combined with Taohuatang to ulcerative colitis with cold-heat complicated syndrome at active stage

and to study regulation effect to immune function and inflammatory response.

Method:

One hundred and twelve patients were randomly divided into control group and observation group by random number table. Patients with light and middle symptoms in control group got mesalazine slow release tablets

1.0 g/time

3 times/days

patients with severe symptoms or whose symptoms were not changed after getting for 4 weeks in control group got prednisone acetate tablets

0.75 mg·kg

-1

·d

-1

for 3 times. Based on the treatment in control group

patients in observation group added Huaihuasan combined with Taohuatang

1 dose/day. The course of treatment was 4 weeks. At remission period

mesalazine slow release tablets were used for maintain long-term maintenance therapy

0.5 g/times

3 times/days. Scores of disease activities were graded by improvement mayo

and clinical remission and clinical efficacy were recorded

scores of cold-heat complicated syndrome

mucous membrane under enteroscopy and histology of mucosa belongs to Geboes were graded. And levels of tumor necrosis factor-

(TNF-

) in peripheral blood

interleukin-8 (IL-8)

IL-10

T lymphocyte subsets (CD4

CD8

)

and adverse reactions

6 months' follow-up and recurrence were also be recorded.

Result:

Therapeutic effect of traditional Chinese medicine syndromes were analyzed by rank sum test

which in observation group was better than that in control group (

=1.915

0.05). Clinical effect in observation group was 98.04%(50/51) higher than 84.00%(42/50) in control group

clinical remission rate was 94.12%(48/51) higher than 78.00%(39/50) in control group

and mucosal healing rate was 96.08%(49/51) higher than 82.00%(41/50) in control group (

0.05). Scores of mayo

cold-heat complicated syndrome

colonic mucosa and index scores of Geboes were all lower than those in control group (

0.01). And levels of TNF-

IL-8 and CD8

were lower than those in control group (

0.01)

and levels of IL-10

CD4

and CD4

/CD8

were higher than those in control group (

0.01). Recurrence rate during 6 months in observation group was 10.42%(5/48) lower than 30.77%(12/39) in control group (

=5.669

0.05)

as for adverse reactions

there was no significant difference between two groups.

Conclusion:

Huaihuasan combined with Taohuatang can induce UC to remission period

inhibit the activity of disease

alleviate clinical symptoms

regulate immune function and expression of inflammatory factors

alleviate inflammatory reaction

promote intestinal mucosal healing

and can maintain clinical remission and reduce recurrence. The clinical efficacy is superior to that of 5-ASA/glucocorticoid in Western medicine.

关键词

Keywords

references

沈洪，邢敬．中西医结合治疗溃疡性结肠炎的优势及临床应用 [J]．医学研究生学报， 2019 ， 32 ( 6 ): 586 - 590 .

张声生，赵鲁卿．溃疡性结肠炎的中医治疗策略和思考 [J]．中国中西医结合消化杂志， 2016 ， 24 ( 6 ): 411 - 413 .

中华中医药学会脾胃病分会．溃疡性结肠炎中医诊疗专家共识意见(2017) [J]．中国中西医结合杂志， 2017 ， 32 ( 8 ): 3585 - 3589 .

冯智，唐学贵，申旭龙，等．基于“血水同病”理论治疗溃疡性结肠炎的体会 [J]．成都中医药大学学报， 2015 ， 38 ( 3 ): 98-99，104 .

罗芬，原相军，占煜，等．仙方活命饮合槐花散加减治疗溃疡性结肠炎31例疗效观察 [J]．湖南中医杂志， 2014 ， 30 ( 1 ): 39 - 41 .

魏妮，孟凡冰，王宗柱．桃花汤治疗溃疡性结肠炎的研究进展 [J]．国医论坛， 2007 ， 22 ( 5 ): 55 - 56 .

中华医学会消化病学分会炎症性肠病学组．炎症性肠病诊断与治疗的共识意见(2012年·广州) [J]．中华内科杂志， 2012 ， 51 ( 10 ): 818 - 831 .

G D'HAENS , W J SANDBORN , B G FEAGAN ， et al . A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis [J]． Gastroenterol ， 2007 ， 132 ( 2 ): 763 - 786 .

K GEBOES , R RIDDELL , A OST ， et al . A reproducible grading scale forhistological assessment of inflammation in ulcerative colitis [J]． Gut ， 2000 ， 47 ( 3 ): 404 - 409 .

中国中西医结合学会消化系统疾病专业委员会．溃疡性结肠炎中西医结合诊疗共识意见(2017年) [J]．中国中西医结合消化杂志， 2018 ， 26 ( 2 ): 105-111，120 .

张旭，周强，吴兵，等．张声生从“寒热”“气血”论治溃疡性结肠炎 [J]．中华中医药杂志， 2018 ， 33 ( 7 ): 2885 - 2887 .

刘明坤，于博文，陶夏平．陶夏平辨治溃疡性结肠炎经验浅析 [J]．中华中医药杂志， 2016 ， 31 ( 10 ): 4081 - 4083 .

贾佼佼，苗明三．槐花的化学、药理及临床应用 [J]．中医学报， 2014 ， 29 ( 5 ): 716-717，745 .

孙文君，周灵君，丁安伟．矿物药赤石脂的研究进展 [J]．广州化工， 2010 ， 38 ( 11 ): 39 - 41 .

张鑫，李建宽，赵玉静，等．党参化学成分及其体外抗氧化活性分析 [J]．中国实验方剂学杂志， 2018 ， 24 ( 24 ): 53 - 59 .

张俊飞，孙广璐，张彬，等．侧柏叶药理作用的研究进展 [J]．时珍国医国药， 2013 ， 24 ( 9 ): 2231 - 2233 .

M HEDL , D D PROCTOR , C ABRAHAM . JAK2 Disease-Risk variants are gain of function and JAK signaling threshold determines innate receptor-induced proinflammatory cytokine secretion in macrophages [J]. J Immunol ， 2016 ， 197 ( 9 ): 3695 - 3704 .

J BASS , V SHAKHNOVICH , E CARPENTER , et al . P-201 cardiac manifestations of pediatric inflammatory bowel disease [J]. Inflamm Bowel Dis , 2016 ， 22 : S69 - S70 .

N EBRAHIMI DARYANI , A SAGHAZADEH , S MOOSSAVI , et al . Interleukin-4 and interleukin-10 gene polymorphisms in patients with inflammatory bowel disease [J]. Immunol Invest , 2017 , 46 ( 7 ): 714 - 720 .

袁柏思，金鑫鑫，路又可，等．溃疡性结肠炎外周血CD3 ＋，CD4 ＋，CD8 ＋ T细胞的活化及其与炎症标志物的关系 [J]．胃肠病学和肝病学杂志， 2015 ， 24 ( 8 ): 939 - 942 .

冯卓，韩昌鹏，李盈，等．祛湿清肠方内服联合中药灌肠治疗轻中度活动期溃疡性结肠炎大肠湿热证临床观察 [J]．中国实验方剂学杂志， 2018 ， 24 ( 5 ): 149 - 154 .

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Exploring Mechanism of Different Processed Products of Baiyaojian and Its Formula in Treating Ulcerative Colitis Based on Serum Metabolomics and Flow Cytometry

Effect of Mankuining Formula on NLRP3/Caspase-1/GSDMD Pyroptosis Pathway and Gut Microbiota in DSS-induced Ulcerative Colitis Mice

Effect of Mankuining Decoction on Expression of Inflammatory Factors and Intestinal Flora in Mice with Ulcerative Colitis

Clinical Observation on Jiechang Qingre Pills Combined with Conventional Western Medicine Therapy in Improving Dampness-heat Syndrome of Large Intestine at Active Stage of Ulcerative Colitis

Exploring Mechanism of Modified Fuzi Lizhongtang in Intervening Inflammatory Response of Intestinal Mucosa in Rats with Ulcerative Colitis Based on mTOR/p-S6K1

Related Author

WANG Ruisheng

HOU Yafang

CAO Wenwen

ZHAO Yahong

ZHANG Zhenling

JI Yongkuan

NI Ruifan

LIANG Yanlin

Related Institution

Henan Collaborative Innovation Center for Research and Development on the Whole Industry Chain of Yu-yao，Henan Engineering Research Center of Chinese Traditional Medicine Special Processing Technology， Henan Engineering Technology Research Center for Integrated Production of Chinese Medicine， Henan Provincial Key Laboratory of Traditional Chinese Medicine for Decoction Pieces Processing， Collaborative Innovation Center for Chinese Medicine and Respiratory Diseases Co-constructed by Henan Province & Ministry of Education，Henan University of Chinese Medicine

School of Traditional Chinese Medicine， Beijing University of Chinese Medicine

Second Clinical Medical College， Henan University of Chinese Medicine

Henan Province Hospital of TCM The Second Affiliated Hospital of Henan University of Chinese Medicine

Affiliated Hospital of Chengdu University of Traditional Chinese Medicine

AI问答

Postal code：100700
Tel：010-84076882 Email：syfjx_2010@188.com
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备11006657号-10 京公网安备11010802024621
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰